GlassScriptPhysician profile
Morgan Cole
NPI 1093166068
$9,218.09
in general payments reported to CMS, 2019-2025
31 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,616 · 2022: $1,303 · 2023: $1,999 · 2024: $2,119 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,724 · Education: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,724.20 |
| Education | $574.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,749.56 | 2021-2025 | |
| Janssen Biotech, INC. | $1,075.53 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $871.54 | 2021-2025 | Ilumya, Winlevi |
| Ucb, INC. | $867.96 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $807.56 | 2021-2025 | |
| Lilly USA, LLC | $806.87 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $280.31 | 2021-2025 | |
| Amgen INC. | $260.88 | 2021-2025 | Otezla, Enbrel, Otezla |
| Regeneron Healthcare Solutions, INC. | $254.38 | 2021-2025 | Dupixent |
| Dermavant Sciences, INC. | $243.26 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $240.08 | 2021-2025 | Nemluvio, Dysport |
| Leo Pharma INC. | $237.26 | 2021-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $188.23 | 2021-2024 | |
| Incyte Corporation | $165.76 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $164.99 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $153.56 | 2022-2024 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $133.80 | 2022-2023 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.59 | 2021 | |
| Biofrontera INC. | $126.29 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.18 | 2023 | Spevigo |
| Sandoz INC. | $77.43 | 2024-2025 | Hyrimoz |
| Genentech USA, INC. | $69.71 | 2021-2024 | Erivedge |
| Sebela Pharmaceuticals INC. | $50.48 | 2021-2023 | Naftin |
| Sobi, INC | $39.79 | 2024 | |
| Dermira, INC. | $27.13 | 2021 | |
| Fresenius Kabi USA, LLC | $26.39 | 2023 | Idacio |
| Organon LLC | $25.39 | 2025 | Vtama |
| Almirall LLC | $21.83 | 2021 | |
| Arcutis Biotherapeutics, INC. | $16.16 | 2023 | |
| Epi Health, LLC | $13.40 | 2022 | |
| Mayne Pharma Commercial LLC | $7.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.